Hendrik E.
- Country
- The Netherlands
- Department
- Intensive Care
Research Overview
- Evaluation of Oseltamivir and Drug Combinations in Hospitalized Patients with Acute Respiratory Tract Infection: A Randomized Adaptive Platform Trial
- Evaluation of Optimized Initial Dosing of Beta-Lactam Antibiotics in Critically Ill ICU Patients with Sepsis: A Study of Flucloxacillin, Amoxicillin, and Ceftriaxone
Data & Insights
Has run more than one trial at 10 of 104 partner sites.
Specializations
Critical Care Medicine
The investigator specializes in critical care medicine with a primary focus on sepsis management in intensive care settings. Their research explores innovative therapeutic approaches for critically ill patients in the ICU environment.
- Sepsis Treatment Optimization
- ICU Patient Care
- Critical Care Interventions
Their work encompasses clinical investigations into dosing strategies and therapeutic interventions for improving patient outcomes in intensive care scenarios.
Emergency Medicine
The investigator's expertise extends to emergency medical care, particularly focusing on early recognition and management of severe infections and septic conditions.
- Emergency Response Protocols
- Acute Care Management
- Treatment Optimization
Their research interests include developing and evaluating clinical protocols for acute care scenarios requiring immediate medical intervention.
Clinical Pharmacology
The investigator focuses on therapeutic dosing strategies and their clinical applications in critical care settings, particularly for patients with severe infections.
- Drug Administration Protocols
- Clinical Outcomes Research
- Treatment Efficacy Studies
Their work involves investigating optimal medication delivery approaches to enhance treatment effectiveness in critically ill patients.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.